Tony Kingsley, Stablix CEO (Scholar Rock)
Vertex buys in on Stablix's protein stabilization approach in research and licensing deal
Roughly two years after Stablix embarked on a mission to stabilize certain proteins whose insufficiency leads to disease, Vertex Pharmaceuticals announced it’s coming along for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
